Alongside aducanumab news, Biogen also impresses with financial results

22 October 2019

News that the company is to file for US approval of the previously dumped Alzheimer’s drug aducanumab is dominating industry news on Tuesday, but Biogen (Nasdaq: BIIB) will also have contented long-term investors with its third-quarter 2019 financial results.

Revenues at the US biotech grew 5% compared to the third quarter of 2018, to $3.62 billion, when analysts had expected around $3.54 billion. A 17% jump in sales of the spinal muscular atrophy drug Spinraza (nusinersen) was a major factor in the increase.

Adjusted earnings per share (EPS) were $9.17, growing 24% from a year ago and above the forecast figure of $8.28, with adjusted net income at $1.49 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK